Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company (Nasdaq, HOTH) focused on developing new generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth owns the exclusive rights to develop the BioLexa Platform™ for all indications in humans. The BioLexa Platform™ is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform™ combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur.
Total Money Raised (as of March 2020): $17,000,000